Bristol-myers Squibb Stock News

Canton Hathaway LLC trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 14.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,538 shares of the biopharmaceutical companys stock after selling 4,505 shares during the quarter. Canton Hathaway LLCs holdings in Bristol-Myers Squibb were []

Unigestion Holding SA reduced its holdings in Bristol-Myers Squibb (NYSE:BMY) by 10.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 234,526 shares of the biopharmaceutical company’s stock after selling 26,039 shares during the quarter. Unigestion Holding SA’s holdings in Bristol-Myers […]

IAM Advisory LLC acquired a new stake in Bristol-Myers Squibb (NYSE:BMY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 11,613 shares of the biopharmaceutical companys stock, valued at approximately $667,000. Other hedge funds and other institutional investors also recently made changes to their []

Many stocks are ridiculously expensive right now -- but not these three.

Bristol-Myers Squibb Co. (BMY) shares closed today at 1.2% above its 52 week low of $56.11, giving the company a market cap of $127B. The stock is currently down 5.2% year-to-date, down 4.3% over the past 12 months, and up 15.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.2%. Trading Activity Trading volume this week was 18.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -138.2% The company's stock price performance over the past 12 months lags the peer average by -123.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Related Stocks: BMY ,

Legacy Advisors LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,835 shares of the biopharmaceutical companys stock after purchasing an additional 362 shares during the period. Legacy Advisors LLCs holdings []

Bristol Myers (BMY) wins EC approval for Zeposia for a second indication ??? ulcerative colitis.

Bristol Myers Squibb (BMY) announced that it has received a Marketing Authorization from the European Commission (EC) for Zeposia (ozanimod) for the treatment of adults with moderately The post Bristol Myers Squibb Gets EC Approval for Zeposia appeared first on Smarter Analyst .

Needless to say, 2021 has been a banner year for equities, with the S&P 500 up a stunning 25%.

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Insights and Forecast to 2027 Glucagon Like Peptide-1 (GLP-1) Agonists Market research performs thorough market analysis and uses a variety of sources to provide key players with wide-ranging knowledge about industry strategies. This analysis

Complete study of the global High Potency API market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of

The European Commission has approved Bristol Myers Squibb & Co''s (NYSE: BMY ) Zeposia (ozanimod) for ulcerative colitis (UC). The approval comes for adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. Zeposia, an oral medication taken once daily, Full story available on Benzinga.com

(RTTNews) - Bristol Myers Squibb (BMY) said on Tuesday that the European Commission or EC has granted marketing authorization for ozanimod, brand named Zeposia for the treatment of adults with moderately to severely active ulcerative colitis or UC who have had an inadequate response, lost response, or were intolerant to either conventional